Oncology Company Announces FDA Clearance of New Solid Tumor Treatment
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors.
Disclaimer: The following article is based on information provided by FibroGen, Inc. (NASDAQ:FGEN) and should not be considered as medical or professional advice. The details within are for informational purposes only and subject to further research and verification. Always consult with a healthcare professional for specific medi…